Semaglutide dosing — how the labels structure titration

Semaglutide dosing, as the labels structure it, follows one pattern: a low starter dose of 0.25 mg once weekly — deliberately sub-therapeutic — is escalated roughly every four weeks until the maintenance dose is reached: up to 2 mg weekly on the Ozempic (diabetes) label and 2.4 mg weekly on the Wegovy (weight management) label, a ramp that takes about 16 weeks (Wegovy prescribing information). The slow climb is not about building efficacy — it exists to keep nausea and vomiting manageable while the gut adapts.

Native GLP-1 lasts about two minutes in circulation. Semaglutide's fatty-diacid chain binds it to albumin and its modified backbone resists the DPP-4 enzyme, stretching the half-life to roughly one week (Knudsen & Lau, Frontiers in Endocrinology 2019). Two practical consequences: one injection covers a week with fairly flat drug levels, and steady state takes 4–5 weeks to reach — which is one reason each titration step in the labels is held for about a month before the next increase.

Both injectable labels use the same architecture, differing only in the ceiling:

• Initiation: 0.25 mg subcutaneously once weekly for four weeks. The labels are explicit that this is a tolerability step, not an effective treatment dose.
• Escalation: the dose steps up approximately every four weeks (through 0.5, 1, and 1.7 mg in the weight-management program).
• Maintenance: up to 2 mg weekly for Ozempic (Ozempic label); 2.4 mg weekly for Wegovy injection (Wegovy label).

Prescribers adapt this map to the person: trials and labels both allow holding a step longer when a dose isn't tolerated, and in practice many patients stay at whichever dose gives a good response. The STEP trials that established the drug's weight effects all used this ~16-week escalation to 2.4 mg (STEP 1, NEJM 2021).

Starting at maintenance doses would front-load the drug's dominant side effects — in the pooled Wegovy trials even the gradual ramp produced nausea in 44% of participants (vs 16% on placebo). GI symptoms cluster around dose increases and settle as the body adapts, so spacing increases about a month apart keeps most people on therapy: 4.3% permanently discontinued because of a gastrointestinal reaction in the Wegovy program (Wegovy label). More on the side-effect profile itself on the side effects page.

Rybelsus (and the newer oral Wegovy tablets) deliver semaglutide daily by mouth rather than weekly by injection. Because so little peptide survives the stomach, the tablet's labeling is strict: taken once daily on an empty stomach with a small amount of water, well before other food, drink, or medications. The oral route was validated in its own trial program — PIONEER 6 established cardiovascular safety in 3,183 patients with type 2 diabetes (NEJM 2019). Oral and injectable milligram numbers are not interchangeable — daily oral doses are far higher than weekly injectable ones because of the absorption gap.

The approved products come as pre-filled pens or tablets: the dose is fixed, measured, and verified. Compounded and gray-market semaglutide replaces that with vials, syringes, and arithmetic — and this is where things go wrong. The FDA has received multiple adverse-event reports, some requiring hospitalization, tied to dosing errors with compounded injectable semaglutide, including patients self-administering incorrect doses and clinicians miscalculating them (FDA). With raw peptide powder the risk compounds further: the actual dose depends on reconstitution volume and on reading insulin-syringe units correctly, with no verification that the vial contains what its label claims.